Spark Therapeutics Inc. (ONCE) Insider Sells $180,420.00 in Stock
Spark Therapeutics Inc. (NASDAQ:ONCE) insider Barge Joseph La sold 3,000 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $60.14, for a total value of $180,420.00. Following the completion of the transaction, the insider now directly owns 8,325 shares in the company, valued at $500,665.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Spark Therapeutics Inc. (NASDAQ:ONCE) traded up 1.84% during trading on Wednesday, hitting $62.97. The stock had a trading volume of 393,046 shares. Spark Therapeutics Inc. has a 12-month low of $21.20 and a 12-month high of $65.99. The stock’s 50 day moving average price is $59.29 and its 200 day moving average price is $49.45. The firm’s market cap is $1.93 billion.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. Spark Therapeutics had a negative return on equity of 26.96% and a negative net margin of 366.76%. The firm had revenue of $1.29 million for the quarter, compared to analyst estimates of $1.17 million. During the same quarter last year, the firm posted ($0.60) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts anticipate that Spark Therapeutics Inc. will post ($3.96) EPS for the current fiscal year.
A number of research analysts have recently weighed in on the company. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a report on Sunday, June 12th. Chardan Capital set a $35.00 target price on Spark Therapeutics and gave the stock a “hold” rating in a research note on Thursday, July 21st. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research note on Thursday, July 14th. Wedbush restated an “underperform” rating and issued a $29.00 target price (up previously from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Finally, Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research note on Thursday, August 11th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. Spark Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $62.27.
Several hedge funds have recently bought and sold shares of ONCE. DIAM Co. Ltd. bought a new position in shares of Spark Therapeutics during the second quarter valued at about $2,263,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Spark Therapeutics by 46.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 7,823 shares of the company’s stock valued at $231,000 after buying an additional 2,465 shares during the period. Opus Point Partners Management LLC bought a new position in shares of Spark Therapeutics during the first quarter valued at about $930,000. DekaBank Deutsche Girozentrale boosted its position in shares of Spark Therapeutics by 29.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 13,800 shares of the company’s stock valued at $679,000 after buying an additional 3,100 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Spark Therapeutics by 7.3% in the first quarter. UBS Asset Management Americas Inc. now owns 152,972 shares of the company’s stock valued at $4,514,000 after buying an additional 10,472 shares during the period. Institutional investors and hedge funds own 78.79% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.